Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLS-M32
- Development stage
- Preclinical
- Lead developer
- MOA Life Plus
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
BLS-M32 is a therapeutic vaccine under preclinical development by MOA Life Plus. It is being investigated for the treatment of sarcopenia, a condition characterized by loss of muscle mass and function, typically associated with aging or certain diseases. The drug falls within the therapeutic area of nervous system diseases. As of April 2025, its highest global R&D status is preclinical and it has not yet entered clinical trials or received regulatory approval in any jurisdiction. Detailed information about its mechanism of action, molecular target(s), or specific modality beyond "therapeutic vaccine" has not been disclosed publicly[1][2].
Beyond the preview
Go deeper on BLS-M32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLS-M32.